The combination of bendamustine (B) and rituximab (R) is efficacious, with favorable toxicity in mantle-cell lymphoma (MCL). In this phase II study, we combined cytarabine with R and B (R-BAC) in patients with MCL age ≥ 65 years who were previously untreated or relapsed or refractory (R/R) after one prior immunochemotherapy treatment.

Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation

Visco, Carlo;Finotto, Silvia;Zanotti, Roberta;Pizzolo, Giovanni;
2013-01-01

Abstract

The combination of bendamustine (B) and rituximab (R) is efficacious, with favorable toxicity in mantle-cell lymphoma (MCL). In this phase II study, we combined cytarabine with R and B (R-BAC) in patients with MCL age ≥ 65 years who were previously untreated or relapsed or refractory (R/R) after one prior immunochemotherapy treatment.
2013
Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neutropenia; Nitrogen Mustard Compounds; Positron-Emission Tomography; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vomiting
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/993281
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus 159
  • ???jsp.display-item.citation.isi??? 142
social impact